Mimetogen Pharmaceuticals USA
Closed portfolio with a later-stage archive tilt
According to ClinicalTrials.gov-derived indexes, Mimetogen Pharmaceuticals USA sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Mimetogen Pharmaceuticals USA: 6 sponsored US clinical trials, none currently recruiting.
Mimetogen Pharmaceuticals USA sponsors 6 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 6 completed. 5 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Keratoconjunctivitis Sicca, with 1 trials.
Upper-quartile sponsor footprint
Mimetogen Pharmaceuticals USA sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
6 total, page 1 of 1
Efficacy and Safety Evaluation of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye
NCT05848128
Tavilermide Ophthalmic Solution for the Treatment of Dry Eye
NCT03925727
A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye Disease
NCT02665234
A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye
NCT02634853
A Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye
NCT01960010
Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye
NCT01257607
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 5 |
Therapeutic Areas
How the Mimetogen Pharmaceuticals USA archive is shaped
6 indexed studies, none listed as recruiting (0% open); 6 completed (100%).
Phase mix: 5 late (III/IV) vs 1 early (I/II) (later-stage heavy).
Top condition: Keratoconjunctivitis Sicca (1 trial), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Mimetogen Pharmaceuticals USA: archived-pipeline peers nationwide
Peers matched on 6 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Mimetogen Pharmaceuticals USA sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 archived trials
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
- 3 Waves Wellness · 0% recruiting · 2 trials
Related
What to do with this Mimetogen Pharmaceuticals USA page
6 registered trials is a research-attention snapshot, not an endorsement of Mimetogen Pharmaceuticals USA or any single study.
- None of Mimetogen Pharmaceuticals USA's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Keratoconjunctivitis Sicca is the condition Mimetogen Pharmaceuticals USA studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Keratoconjunctivitis Sicca trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Mimetogen Pharmaceuticals USA pipeline card: 6 registered trials from official public datasets.Report a data error.